These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6205938)

  • 21. Convalescent burn plasma therapy for severely burned children. Control study of 81 cases and tests for Pseudomonas antibodies.
    Bocanegra M; Hinostroza F; Bazan A; Velarde N; Yoza V; Rosenthal SM
    Ann Surg; 1966 Mar; 163(3):461-9. PubMed ID: 4955895
    [No Abstract]   [Full Text] [Related]  

  • 22. The first clinical trial of immuno's experimental Pseudomonas aeruginosa flagellar vaccines.
    Crowe BA; Enzersberger O; Schober-Bendixen S; Mitterer A; Mundt W; Livey I; Pabst H; Kaeser R; Eibl M; Eibl J
    Antibiot Chemother (1971); 1991; 44():143-56. PubMed ID: 1801633
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of thermal injury with Pseudomonas aeruginosa infection on pulmonary and systemic bacterial clearance.
    Wilkinson RA; Fishman JA
    J Trauma; 1999 Nov; 47(5):912-7. PubMed ID: 10568721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of immunological preparations and their use for preventing and treating pyocyanic infection in burn patients].
    Kolker II; Stanislavskiĭ ES; Grishina IA; Panova IuM; Krokhina MA
    Probl Gematol Pereliv Krovi; 1981 Jan; 26(1):29-33. PubMed ID: 6784114
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pseudomonas multicomponent vaccine in major burn patients].
    Mizuno H; Ashikawa K
    Nihon Rinsho; 1991 Oct; 49(10):2425-30. PubMed ID: 1749100
    [No Abstract]   [Full Text] [Related]  

  • 26. [Comparative study of the antibody concentration and protective activity against Pseudomonas aeruginosa of gamma-globulin and IgM-enriched immunoglobulin preparations].
    Kiseleva IA; Kandiurina VG; Timofeeva GV
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Apr; (4):68-71. PubMed ID: 2424197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effectiveness of tobramycin and immunologic preparations in experimental Pseudomonas infection].
    Minukhin VV; Tsyganenko AIa
    Antibiot Khimioter; 1989 Apr; 34(4):282-6. PubMed ID: 2502083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Obtaining antisera to Pseudomonas aeruginosa and Proteus antigens for performing immunoenzyme analyses in clinical practice].
    Bulava GV; Ermolin GA
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Jan; (1):51-5. PubMed ID: 3920845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protection against Pseudomonas aeruginosa infection by immunisation with fractions of culture filtrates of Ps. aeruginosa.
    Jones RJ
    Br J Exp Pathol; 1968 Oct; 49(5):411-20. PubMed ID: 4973304
    [No Abstract]   [Full Text] [Related]  

  • 30. Antibody response in patients with Pseudomonas aeruginosa infection to a 'common antigen' from P. aeruginosa analysed by means of quantitative immunoelectrophoretic methods.
    Høiby N; Hertz JB; Sompolinsky D
    Acta Pathol Microbiol Scand C; 1980 Jun; 88(3):149-54. PubMed ID: 6778073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serologic and protective cross-reactivity of antisera to Pseudomonas aeruginosa extracellular slime glycolipoprotein.
    Yushkova NA; Kholodkova EV; Korobova TS; Stanislavsky ES
    Acta Microbiol Hung; 1986; 33(2):147-56. PubMed ID: 3101393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of common polysaccharide antigen of Pseudomonas aeruginosa with O-antiserum to Pseudomonas cerasi.
    Kocharova NA; Knirel YA; Romanowska A; Romanowska E; Makarenko TA; Edvabnaya LS; Stanislavsky ES; Zdorovenko GM; Yakovleva LM
    FEMS Microbiol Immunol; 1991 Apr; 3(2):69-73. PubMed ID: 1713775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective efficacy of Pseudomonas aeruginosa type-A flagellin in the murine burn wound model of infection.
    Faezi S; Safarloo M; Amirmozafari N; Nikokar I; Siadat SD; Holder IA; Mahdavi M
    APMIS; 2014 Feb; 122(2):115-27. PubMed ID: 23758581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunization against Pseudomonas in infection after thermal injury.
    Wesley J; Fisher A; Fisher MW
    J Infect Dis; 1974 Nov; 130 Suppl(0):S152-8. PubMed ID: 4138646
    [No Abstract]   [Full Text] [Related]  

  • 35. [Production of a hyperimmune antitoxic donor plasma against Pseudomonas aeruginosa].
    Krokhina MA; Davatdarova GM; Cherkas GP; Podgornaia LG; Shinkarenko AA
    Zh Mikrobiol Epidemiol Immunobiol; 1980 Sep; (9):78-83. PubMed ID: 6778040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunological properties of the Gram-negative bacilli Pseudomonas aeruginosa].
    Rusiecka-Ziółkowska J; Fleischer M; Staroszczyk J
    Postepy Hig Med Dosw (Online); 2007; 61():95-8. PubMed ID: 17369777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Advisability of using donor blood immunoglobulin preparations for treating infections caused by Pseudomonas aeruginosa].
    Nazarchuk LV
    Klin Khir (1962); 1991; (1):23-4. PubMed ID: 1712409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models.
    Yang F; Gu J; Yang L; Gao C; Jing H; Wang Y; Zeng H; Zou Q; Lv F; Zhang J
    Sci Rep; 2017 Jun; 7(1):3957. PubMed ID: 28638106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibodies raised against divalent type b flagellin and pilin provide effective immunotherapy against Pseudomonas aeruginosa infection of mice with burn wounds.
    Saffari M; Behbood S; Irajian G; Khorshidi A; Moniri R; Behrouz B
    Biologicals; 2017 Jan; 45():20-26. PubMed ID: 27836582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological determinants of pseudomonas infections of man accompanying severe burn injury.
    Alexander JW; Fisher MW
    J Trauma; 1970 Jul; 10(7):565-74. PubMed ID: 4986708
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.